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Isoniazid Resistance and Death in Patients With Tuberculous Meningitis:
Retrospective Cohort Study
Abstract
Objective To determine whether initial isoniazid resistance is associated with death during the treatment of
tuberculous meningitis.
Design Retrospective cohort study.
Setting National Tuberculosis Surveillance System at the Centers for Disease Control in the United States.
Participants Patients with a clinical diagnosis of tuberculous meningitis, reported to the National
Tuberculosis Surveillance System between 1 January 1993 and 31 December 2005.
Main outcome measure All cause mortality during antituberculous treatment.
Results Between 1993 and 2005, 1896 patients had a clinical diagnosis of tuberculous meningitis and positive
cultures from any site. In 123 (6%) of these patients, isoniazid resistance was present on initial susceptibility
testing. The unadjusted association between initial isoniazid resistance and subsequent death among these
1896 patients did not reach statistical significance (odds ratio 1.38, 95% confidence interval 0.94 to 2.02).
However, among 1614 patients with positive cerebrospinal fluid cultures, a significant unadjusted association
was found between initial isoniazid resistance and subsequent death (odds ratio 1.61, 1.08 to 2.40). This
association increased after adjustment for age, race, sex, and HIV status (odds ratio 2.07, 1.30 to 3.29).
Conclusions Isoniazid resistance on initial susceptibility testing was associated with subsequent death among
cases of tuberculous meningitis with positive cerebrospinal fluid cultures. Randomised controlled trials are
needed to evaluate the optimal empirical regimen for treating patients with tuberculous meningitis who are at
high risk for both initial isoniazid resistance and poor clinical outcomes.
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Isoniazid resistance and death in patients with tuberculous
meningitis: retrospective cohort study
Christopher Vinnard, fellow,1,2 Carla AWinston, senior epidemiologist,3 E Paul Wileyto, assistant professor,2,4
Rob Roy MacGregor, professor emeritus,1 Gregory P Bisson, assistant professor1,2
ABSTRACT
Objective To determine whether initial isoniazid
resistance is associated with death during the treatment
of tuberculous meningitis.
Design Retrospective cohort study.
Setting National Tuberculosis Surveillance System at the
Centers for Disease Control in the United States.
Participants Patients with a clinical diagnosis of
tuberculous meningitis, reported to the National
Tuberculosis Surveillance System between 1 January
1993 and 31 December 2005.
Main outcome measure All cause mortality during
antituberculous treatment.
Results Between 1993 and 2005, 1896 patients had a
clinical diagnosis of tuberculous meningitis and positive
cultures from any site. In 123 (6%) of these patients,
isoniazid resistance was present on initial susceptibility
testing. The unadjusted association between initial
isoniazid resistance and subsequent death among these
1896 patients did not reach statistical significance (odds
ratio 1.38, 95% confidence interval 0.94 to 2.02).
However, among 1614 patients with positive
cerebrospinal fluid cultures, a significant unadjusted
association was found between initial isoniazid resistance
and subsequent death (odds ratio 1.61, 1.08 to 2.40). This
association increased after adjustment for age, race, sex,
and HIV status (odds ratio 2.07, 1.30 to 3.29).
Conclusions Isoniazid resistance on initial susceptibility
testing was associated with subsequent death among
cases of tuberculous meningitis with positive
cerebrospinal fluid cultures. Randomised controlled trials
are needed to evaluate the optimal empirical regimen for
treating patients with tuberculous meningitis who are at
high risk for both initial isoniazid resistance and poor
clinical outcomes.
INTRODUCTION
Tuberculous meningitis is the most devastating mani-
festation of tuberculosis. As a consequence of the mer-
ging of the HIV and tuberculosis epidemics,
tuberculosis has become the most common cause of
bacterial meningitis in some areas.1 2 Starting effective
anti-tuberculous treatment early is essential for a suc-
cessful outcome.3 Among the first line drugs, isoniazid
is the only bactericidal agent that easily crosses the
blood-brain barrier, achieving concentrations in
cerebrospinal fluid similar to those in serum.45 Rifam-
picin, ethambutol, and streptomycin all penetrate
cerebrospinal fluid poorly, even in the setting of
meningeal inflammation.6-8 Pyrazinamide freely
crosses the blood-brain barrier, but its role in tubercu-
lous meningitis is uncertain given its bacteriostatic
activity against older, resting bacilli.9 10 Isoniazid also
has the strongest early bactericidal activity of all first
line agents, defined as the reduction of bacillary load
during the first two days of anti-tuberculous
treatment.11 12
Guidelines for the management of drug resistant
tuberculosis are based on analysis of evidence from
trials of pulmonary tuberculosis done by the British
Medical ResearchCouncil,13 inwhich resistance to iso-
niazid was not associated with adverse outcomes when
combination treatment with ethambutol, rifampicin,
and pyrazinamide was used. This experience has
informed recommendations for treatment of other
forms of tuberculosis, including tuberculous
meningitis.14 However, given important differences
between tuberculousmeningitis and pulmonary tuber-
culosis with respect to the anatomical locations of
organisms, mechanisms of host injury, and rapidity of
disease progression, the role of anti-tuberculous drug
resistance in tuberculous meningitis deserves an inde-
pendent examination.15
In other types of bacterial meningitis, bactericidal
activity and penetration of cerebrospinal fluid are anti-
microbial properties relevant for clinical cure.16 There-
fore, isoniazid resistance in tuberculous meningitis
may affect treatment outcomes to an extent that has
not been seen for pulmonary tuberculosis. During the
interval of time needed to obtain results from initial
anti-tuberculous drug susceptibility testing (typically
six to eight weeks), irreversible progression of disease
may have occurred. Whereas previous studies of the
associationbetween initial isoniazid resistance andout-
come of treatment have been limited by small sample
sizes,17 the tuberculosis surveillance dataset main-
tained by theCenters forDiseaseControl in theUnited
States offers a uniqueopportunity to study this relation.
We tested the hypothesis that initial isoniazid resis-
tance would be associated with adverse outcomes in
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patients being treated for an initial episode of tubercu-
lous meningitis.
METHODS
Setting
We analysed data from the National Tuberculosis Sur-
veillance System at the Centers for Disease Control,
which has collected aggregate data on cases of tubercu-
losis since 1953 and patient specific data (including
information on drug susceptibility) since 1993. State
health departments report cases of tuberculosis by
using the report of verified case of tuberculosis stan-
dard form, an anonymous reporting mechanism that
consists of an initial report and two follow-up
reports.18 A case must satisfy a standardised tuberculo-
sis case definition to be included in the national count.
A multi-state study that used multiple secondary
sources to ascertain unreported cases found the com-
pleteness of the tuberculosis reporting system to be
99.5%.19
Clinical and demographic data are collected in the
initial report as described extensively elsewhere.18 For
each case with a positive culture or smear, the anato-
mical site is included in the initial report. The initial
drug regimen is reported, alongwith the date that treat-
ment started. For all states except California, HIV sta-
tus is included in the report. For California, HIV status
is obtained by linking with the California AIDS regis-
try, which does not include HIV positive people with-
out AIDS. No matching with the California AIDS
registry has occurred since 2004. Results for patients
with negative HIV tests are also unavailable for cases
in California.
Approximately 80% of cases of tuberculosis
reported to the Centers for Disease Control are culture
positive, and approximately 97% of culture positive
cases have accompanying drug susceptibility data,
which are included in the first follow-up report. The
second follow-up report includes the date treatment
stopped and reasons for stopping treatment, which
are “completed therapy,” “moved,” “lost,” “unco-
operative or refused,” “not TB,” “died,” “other,” and
“unknown.”
Participants
Our analysis examined data on all cases of tuberculosis
reported between 1 January 1993 and 31 December
2005, which allowed for at least two years of follow-
up. We selected patients for inclusion if a meningeal
site of involvement was reported and if they were
alive at diagnosis and started anti-tuberculous treat-
ment. We excluded patients with a previous diagnosis
of tuberculosis, as we reasoned that these patients may
be treated differently by clinicians on the basis of
known or suspected drug resistance from previous
treatment histories. To test the hypothesis that initial
isoniazid resistance is associated with subsequent
death, we limited the analysis to patients with a diag-
nosis of tuberculous meningitis, a positive culture for
Mycobacterium tuberculosis from any site, and initial iso-
niazid susceptibility data. We excluded patients with
initial resistance to both isoniazid and rifampicin
(multi-drug resistance).
Statistical methods
We determined the unadjusted association between
initial isoniazid resistance and subsequent death by
using the χ2 test. We calculated an odds ratio and a
95% confidence interval to evaluate the strength of
the association and the precision of the effect. We
then stratified the association of initial isoniazid resis-
tance and subsequent death according to whether the
patient was infected with HIV and whether the patient
had a positive cerebrospinal fluid culture.
We screened other demographic and clinical factors
for inclusion in amultivariate logistic regressionmodel
on the basis of unadjusted associations with death
(P<0.25). We treated age categorically because it was
not normally distributed. Once we had identified vari-
ables for further evaluation in the multivariate model,
we usedmultiple imputation for variables withmissing
observations. We determined clinical and demo-
graphic variables to have missing observations if the
variable was listed as “not done” or “unknown” or
had a missing response. Observations with missing
values were not a random sample of the entire dataset,
as is the case with “missing completely at random”
data. Rather, whether certain clinical variables (such
as HIV status) were missing depended on other vari-
ables in the dataset (such as age and race), creating a
“missing at random” pattern. With such data, remov-
ing participants with missing observations from the
analysis will lead to a biased sampling of the study
population, and for this reason we chose multiple
imputation as the approach to handle missing data.
The final estimates in the multivariate model came
from five imputed datasets.20
Variables remained in the model if they changed the
odds ratio for isoniazid resistance and subsequent death
bymore than15%.For clinical reasons, sexandHIVco-
infection remained in the finalmodel, regardless of their
effect on the association of interest. We evaluated
whether a statistically significant interactionwas present
between HIV co-infection and initial isoniazid resis-
tance, as well as between positive cerebrospinal fluid
cultures and initial isoniazid resistance. We did a sec-
ondary analysis limited to adults initially treated with
isoniazid, rifampicin (or rifabutin), pyrazinamide, and
ethambutol. Finally,we did sensitivity analyses examin-
ing different approaches to handling missing HIV sta-
tus, as well as different assumptions about the patients
who were lost to follow-up. We used STATA v10.0 for
all statistical calculations.
RESULTS
Unadjusted analyses
A total of 3114 cases of tuberculous meningitis were
reported to the Centers for Disease Control between
1 January 1993 and 31 December 2005, and 3023
(97%) occurred in people without a previous diagnosis
of tuberculosis. After exclusion of 967 patients lacking
positive cultures from any site, 131 patients without
RESEARCH
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isoniazid susceptibility results, and 29 patients with
multi-drug resistant disease, 1896 patients remained
for analysis (figure).
Of these 1896 patients, 1614 (85%) had a positive
culture from cerebrospinal fluid and 282 (15%) had
positive cultures only from other sites. Five hundred
and forty-one (29%) patients died during treatment.
Of the remaining 1355 patients, 1177 (87%) completed
treatment and 178 (13%) were lost to follow-up.
Among patients who completed treatment, themedian
duration of treatment was 366 days for isoniazid sus-
ceptible disease and 438 days for isoniazid resistant
disease. For patients who died, the median duration
of treatment was 37 days for isoniazid susceptible dis-
ease and 52 days for isoniazid resistant disease. For
patients who were lost to follow-up, the median dura-
tion of treatment was 146 days for isoniazid susceptible
disease and 190 days for isoniazid resistant disease.
One hundred and twenty-three (6%) patients had iso-
niazid resistance on initial drug susceptibility testing.
Overall, 43 (35%) of 123 patients with initial isoniazid
resistance died during treatment, compared with 498
(28%) of 1773 patients without isoniazid resistance
(odds ratio 1.38, 95% confidence interval 0.94 to 2.02).
Among all patients, 989 (52%) had known HIV sta-
tus (404 HIV positive, 585 HIV negative) and 907
(48%) had unknown HIV status. HIV was not asso-
ciated with initial isoniazid resistance (P=0.6) among
patients with known HIV status, although it was
strongly associated with death (odds ratio 4.20, 3.16
to 5.59).
When restricted to patients with known HIV status,
the unadjusted association between isoniazid resis-
tance and death was not significant among HIV posi-
tive or HIV negative patients. Specifically, among
known HIV positive patients, 16 deaths occurred
among 29 patients with isoniazid resistant disease and
181 deaths among 375 patients with isoniazid suscep-
tible disease (odds ratio 1.32, 0.63 to 2.78). Among
known HIV negative patients, six deaths occurred
among 37 patients with isoniazid resistant disease and
102 deaths among 548 patients with isoniazid
susceptible disease (odds ratio 0.85, 0.35 to 2.03). As
both stratum specific associations (odds ratios)
included the null value of 1, known HIV infection
was not a significant effect modifier of the relation
between initial isoniazid resistance and subsequent
death.
In unadjusted analysis stratified by the presence or
absence of a positive cerebrospinal fluid culture, the
increased risk of death in patients with initial isoniazid
resistance was limited to patients with a positive
cerebrospinal fluid culture. Among 1614 patients
with a positive cerebrospinal fluid culture, 43 (39%)
of 109with initial isoniazid resistancediedduring treat-
ment, compared to 433 (29%) of 1505 patients without
initial isoniazid resistance (odds ratio 1.61, 1.08 to
2.40). Among the 282 patients with a positive culture
from a non-cerebrospinal fluid site, none of the 14
patients with initial isoniazid resistance died (odds
ratio 0, 0 to 0.87).
Adjusted analyses
Table 1 shows the characteristics screened for inclusion
in the multivariate logistic regression model, the num-
ber of non-missing observations for each characteristic,
the proportion of patients with each characteristic
according to treatment outcome, and the unadjusted
odds ratios for the outcome of death during treatment.
In the adjusted analysis, advancing age and race were
the only significant confounders of the association
between initial isoniazid resistance and death. We
found no interaction betweenHIV status and initial iso-
niazid resistance (P=0.7). In contrast, a significant inter-
action existed between isoniazid resistance and positive
cerebrospinal fluid cultures (P<0.001).Among the 1614
patients with positive cerebrospinal fluid cultures, the
odds ratio for initial isoniazid resistance and death was
2.07 (1.30 to 3.29). Table 2 shows the individual odds
ratios for the other variables among patients with posi-
tive cerebrospinal fluid cultures.
Secondary analyses
As the biological rationale of this investigation rested
on the pharmacological properties of the first line
agents, we did a secondary analysis of 1050 adults
(older than 14 years) with positive cerebrospinal fluid
cultures treated initially with isoniazid, rifampicin (or
rifabutin), ethambutol, and pyrazinamide (odds ratio
for initial isoniazid resistance and subsequent death
2.14, 1.25 to 3.64).
Multiple imputation assumes that whether an obser-
vation is missing does not depend on unobserved vari-
ables. The reporting of HIV status for residents of
California occurs only for patients listed in the AIDS
registry, and not for patients who tested negative for
HIV, which violates this assumption. To test the sensi-
tivity of our results to this mechanism, we repeated the
analysis after imputing HIV status for all California
residents, without matching to the AIDS registry
(odds ratio for initial isoniazid resistance and subse-
quent death among patients with positive cerebro-
spinal fluid cultures 2.12, 1.34 to 3.36).
Cases of clinical tuberculous meningitis reported in United States, 1993-2005 (n=3114)
Cases with previous diagnosis of tuberculosis (n=91)
Cases without previous diagnosis of tuberculosis (n=3023)
Cases without positive cultures for Mycobacterium tuberculosis (n=967)
Cases with positive cultures from any site (n=2056)
Cases without susceptibility testing to isoniazid (n=131)
Cases with susceptibility testing to isoniazid (n=1925)
Cases of tuberculous meningitis analysed (n=1896)
Cases with Mycobacterium tuberculosis resistant to isoniazid and rifampicin (n=29)
Selection of cases for primary analysis
RESEARCH
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Intravenous drug use, non-intravenous drug use,
and alcohol use were all associated with subsequent
death in unadjusted analysis, yet these characteristics
were not associated with isoniazid resistant disease
among patients with known status. In a sensitivity ana-
lysis, we found that the potential for unmeasured con-
founding due to missing observations for these three
characteristics was minimal.
Finally, we investigated the extent to which loss to
follow-up could have influenced the observed associa-
tion. Firstly,we excluded 178 patientswith an outcome
other than completion or death and repeated the steps
of the primary analysis (odds ratio 2.22, 1.37 to 3.60).
Secondly,we introducednon-differentialmisclassifica-
tion of outcome among patients lost to follow-up, ran-
domly assigning 50% of those patients to the outcome
of death, regardless of exposure status (odds ratio 1.90,
1.24 to 2.92). Thirdly, we introduced differential mis-
classification of outcome, by randomly re-assigning
25% of patients lost to follow-up to death in the isonia-
zid susceptible category but none in the isoniazid resis-
tant category (odds ratio 1.74, 1.10 to 2.76). None of
these modifications changed the conclusion that initial
isoniazid resistance was associated with subsequent
Table 1 | Unadjusted analysis of characteristics associated with death (n=1896). Values are numbers (percentages) unless
stated otherwise
Characteristics
Death
(n=541)
Other outcomes
(n=1355)
Unadjusted odds ratio for death
(95% CI)
Isoniazid resistance on initial susceptibility testing:
Overall 43 (8) 80 (6) 1.38 (0.94 to 2.02)
Positive cerebrospinal fluid culture 43/476 (9) 66/1138 (6) 1.61 (1.08 to 2.40)
Culture from non-cerebrospinal fluid site 0/65 (0) 14/217 (6) 0 (0 to 0.87)
Age categories (years):
≤1 4 (1) 85 (6) 0.17 (0.04 to 0.49)
>1 to ≤4 8 (1) 114 (8) 0.26 (0.10 to 0.56)
>4 to ≤14 6 (1) 52 (4) 0.43 (0.14 to 1.05)
>14 to ≤24 23 (4) 100 (7) 0.85 (0.48 to 1.47)
>24 to ≤34 67 (12) 247 (18) Reference
>34 to ≤44 124 (23) 263 (19) 1.74 (1.22 to 2.49)
>44 to ≤54 96 (18) 188 (14) 1.88 (1.29 to 2.76)
>54 to ≤64 61 (11) 123 (9) 1.83 (1.19 to 2.81)
>64 to ≤74 82 (15) 112 (8) 2.70 (1.79 to 4.07)
>74 70 (13) 71 (5) 3.63 (2.32 to 5.69)
Race: (n=537) (n=1342)
White, non-Hispanic 85 (16) 188 (14) Reference
Black, non-Hispanic 231 (43) 458 (34) 1.12 (0.82 to 1.53)
Hispanic 148 (28) 432 (32) 0.76 (0.55 to 1.06)
Asian/native Hawaiian, non-Hispanic 62 (12) 256 (19) 0.54 (0.36 to 0.79)
American Indian, non-Hispanic 11 (2) 8 (1) 3.04 (1.07 to 9.01)
Male sex 351 (65) 799 (59) 1.29 (1.05 to 1.58)
HIV positive 197/305 (65) 207/684 (30) 4.20 (3.16 to 5.59)
Occupation:
Unemployed 318/421 (76) 747/1186 (63) Reference
Healthcare worker 9/421 (2) 43/1186 (4) 0.49 (0.21 to 1.04)
Other 94/421 (22) 396/1186 (33) 0.56 (0.43 to 0.73)
Injecting drug use within previous year 44/419 (11) 49/1192 (4) 2.74 (1.80, 4.17)
Drug use (non-injecting) within previous year 47/410 (11) 80/1183 (7) 1.79 (1.22, 2.60)
Alcohol use within previous year 70/406 (17) 111/1180 (9) 2.01 (1.45, 2.77)
Homeless within previous year 29/486 (6) 57/1278 (4) 1.36 (0.86 to 2.15)
Pulmonary disease 226 (42) 511 (38) 1.19 (0.97 to 1.45)
Positive acid fast bacilli smear of sputum 89/260 (34) 154/570 (27) 1.41 (1.03 to 1.93)
Positive sputum culture 165/246 (67) 303/531 (57) 1.53 (1.12 to 2.10)
Abnormal chest radiograph 321/507 (63) 720/1290 (56) 1.37 (1.11 to 1.69)
Resident of correctional facility at diagnosis 20/537 (4) 30/1349 (2) 1.70 (0.96 to 3.00)
Resident of long term care facility at diagnosis 26/513 (5) 55/1319 (4) 1.23 (0.76 to 1.97)
Foreign birth 185/532 (35) 591/1347 (44) 0.68 (0.55 to 0.84)
Positive tuberculin skin test 120/275 (44) 543/880 (62) 0.48 (0.37 to 0.63)
Positive acid fast bacilli smear from non-sputum specimen 167/470 (36) 367/1163 (32) 1.20 (0.95 to 1.50)
Positive cerebrospinal fluid culture 476 (88) 1138 (84) 1.40 (1.04 to 1.88)
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death among cases of tuberculousmeningitiswith posi-
tive cerebrospinal fluid cultures.
DISCUSSION
In this national cohort of people with tuberculous
meningitis, isoniazid resistance on initial susceptibility
testing was associated with subsequent death among
those with a positive cerebrospinal fluid culture for M
tuberculosis. This association was independent of age
and HIV status and remained robust in a secondary
analysis limited to adults treated initially with isonia-
zid, rifampicin (or rifabutin), ethambutol, and pyrazi-
namide and in sensitivity analyses that considered loss
to follow-up.
Comparison with previous studies
Outcomes of treatment for tuberculous meningitis are
poor when resistance to both isoniazid and rifampicin
is present.21 Isoniazid is unique among the first line
anti-tuberculous agents for its dual properties of high
penetration of cerebrospinal fluid and bactericidal
activity againstM tuberculosis. Concentrations of rifam-
picin in cerebrospinal fluid during treatment for tuber-
culous meningitis are typically within the range of the
minimum inhibitory concentration for M tuberculosis,
which may be inadequate for rapid sterilisation of
cerebrospinal fluid.4 With initial isoniazid resistance,
the four drug regimen is left without a bactericidal
agent with high levels of cerebrospinal fluid penetra-
tion. That the detrimental effect of isoniazid resistant/
rifampicin susceptible disease is intermediate between
drug susceptible and multi-drug resistant disease
should not be surprising. Our findings also build on
an earlier study showing delayed cerebrospinal fluid
sterilisation in cases of tuberculous meningitis that are
resistant to either isoniazid or streptomycin.22
Although reviews of trials from the British Medical
ResearchCouncil suggested that four drug treatment is
an adequate empirical regimen in the setting of isonia-
zid resistance,13 23 a recent meta-analysis of a larger
number of clinical trials has highlighted the uncer-
tainty in this area.24 We found that isoniazid resistance
is a threat to the successful treatment of tuberculosis
when meningeal involvement is present. The narrow
time window between starting treatment and death,
relative to the time needed for culture and susceptibil-
ity results, makes the choice of empirical treatment for
tuberculous meningitis a critical decision. The use of
rapid, molecular assays for drug susceptibility testing
would provide earlier identification of drug resistant
cases of tuberculous meningitis and should be evalu-
ated further.25
Strengths and limitations
This study had several limitations. Although the exact
cause of death is not reported, we believed it to be unli-
kely that a significant proportion of patients who
stopped treatment owing to death would have died
for reasons unrelated to the underlying disease pro-
cess, given the severity of disease characteristic of
tuberculousmeningitis.We could not measure clinical
outcomes other than death during treatment. Survi-
vors of tuberculous meningitis are often left with con-
siderable neurological disability, and we could not
assess the effect of initial isoniazid resistance on rele-
vant non-fatal outcomes.26 We also were unable to
measure the use of adjunctive corticosteroids, which
was associated with decreased mortality in a rando-
mised controlled clinical trial.27
We handled missing data by the method of multiple
imputation. This approach permits complete data
methods for analysis, reduces bias due to missing
data, and incorporates imputation error into standard
errors.28-30 The variable with the greatest degree of
missing data was HIV status (unknown in 48% of
cases). Among patients with known HIV status, HIV
infection was not associated with initial isoniazid resis-
tance (P=0.6). Furthermore, HIV status was not a con-
founder of the association between initial isoniazid
resistance and subsequent death. An absence of asso-
ciation betweenHIV infection and isoniazid resistance
has also been noted in studies of all cases of tuberculo-
sis in the surveillance datasets of the United States and
the United Kingdom.31 32 Therefore, unmeasured con-
founding byHIV status would be unlikely to be strong
enough to explain the association between initial iso-
niazid resistance and subsequent death.
In considering the effect of loss to follow-up, we
found that the association of initial isoniazid resistance
and subsequent death remained significant even with
25% differential misclassification of loss to follow-up.
This degree of differential misclassification is unlikely
given the difference in median duration of treatment
Table 2 | Multivariate logistic regression model for death among 1614 patients with positive
cerebrospinal fluid cultures
Characteristic Odds ratio (95% CI) P value
Isoniazid resistance 2.07 (1.30 to 3.29) 0.002
Male sex 1.20 (0.88 to 1.63) 0.243
Age categories (years): Overall <0.001
≤1 0.076 (0.008 to 0.69) 0.022
>1 to ≤4 0.23 (0.067 to 0.82) 0.023
>4 to ≤14 0.38 (0.102 to 1.41) 0.144
>14 to ≤24 1.22 (0.64 to 2.34) 0.540
>24 to ≤34 Reference
>34 to ≤44 1.30 (0.87 to 1.92) 0.197
>44 to ≤54 1.97 (1.23 to 3.15) 0.005
>54 to ≤64 1.83 (1.09 to 3.09) 0.023
>64 to ≤74 4.36 (2.48 to 7.67) <0.001
>74 6.90 (3.85 to 12.38) <0.001
Race categories: Overall <0.001
White, non-Hispanic Reference
Black, non-Hispanic 1.44 (1.01 to 2.06) 0.046
Hispanic 1.21 (0.74 to 1.99) 0.431
Asian*, non-Hispanic 0.64 (0.30 to 1.35) 0.220
American Indian, non-Hispanic 9.07 (2.65 to 31.02) <0.001
Other†, non-Hispanic 0.85 (0.20 to 3.52) 0.819
HIV positive 3.57 (1.87 to 6.82) 0.002
*Includes Pacific Islander and native Hawaiian categories.
†Includes multiple race and unknown categories.
RESEARCH
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between patients who were lost to follow-up and
patients who died.
Conclusions and policy implications
On a global scale, the mortality from tuberculous
meningitis attributable to isoniazid resistance will be
greater when isoniazid resistance among newly diag-
nosed cases is more common.33 In addition, the rela-
tion between initial isoniazid resistance and death may
be different in settings without access to second line
anti-tuberculous drugs with demonstrated activity in
the central nervous system (such as cycloserine or the
fluoroquinolones),34 or in settings without readily
available neurosurgical services. Recommendations
for the treatment of tuberculosis suggest the use of an
empirically expanded regimen for seriously ill patients
when drug resistance is suspected.14 Our findings lend
strength to this recommendation by showing an
increased risk of death in patients with tuberculous
meningitis and initial isoniazid resistance. Identifica-
tion of risk factors for isoniazid resistance among
patients with tuberculous meningitis could help clini-
cians with the choice of empirical treatment. Rando-
mised controlled trials are needed to evaluate the
optimal empirical regimen for patients with tubercu-
lous meningitis who are at high risk for both initial iso-
niazid resistance and poor clinical outcomes.
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